Comprehensive medication guide to Sinemet including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$15 copay for generic IR tablets on most commercial and Medicare plans (Tier 1–2 preferred generic). Generic ER tablets are Tier 1–2 on most plans; brand-name Rytary and Crexont are Tier 3–4 and typically require prior authorization.
Estimated Cash Pricing
$8–$17 retail for generic IR tablets (30-day supply); as low as $9 with a GoodRx or SingleCare coupon. Generic ER tablets run $50–$80 retail per month, dropping to approximately $29 with GoodRx Gold.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Sinemet is a brand-name prescription medication containing two active ingredients: carbidopa and levodopa. It is classified as a dopaminergic antiparkinsonism agent and has been the gold-standard treatment for Parkinson's disease for more than five decades. The brand-name Sinemet (originally manufactured by Merck) has been discontinued, but generic carbidopa/levodopa remains widely available and therapeutically equivalent.
The FDA has approved carbidopa/levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism caused by carbon monoxide or manganese poisoning. It works by replenishing dopamine in the brain—the neurotransmitter destroyed by Parkinson's disease—to reduce symptoms including tremors, muscle stiffness, slowness of movement, and postural instability.
Available formulations include immediate-release (IR) tablets, extended-release (ER/CR) tablets, extended-release capsules (Rytary, Crexont), and an enteral suspension (Duopa) for advanced patients. As of 2026, ER tablets are in active shortage while IR tablets remain generally available.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Parkinson's disease destroys dopaminergic neurons in the substantia nigra, a brain region critical for movement control. Dopamine cannot be given directly because it cannot cross the blood-brain barrier. Levodopa, the active precursor in Sinemet, does cross the blood-brain barrier and is converted to dopamine in the brain by the enzyme aromatic amino acid decarboxylase (AADC).
Without carbidopa, more than 95% of levodopa would be converted to dopamine in the bloodstream before reaching the brain—causing significant nausea, vomiting, and low blood pressure while wasting most of the dose. Carbidopa inhibits peripheral AADC without crossing into the brain itself, protecting levodopa from premature breakdown and allowing a 70–80% lower effective dose with fewer side effects.
Dietary amino acids (from protein-rich foods) compete with levodopa for absorption in the gut and transport across the blood-brain barrier. This is why patients are advised to take Sinemet 30–60 minutes before meals and to avoid large protein-rich meals around dosing time.
10 mg/100 mg — immediate-release tablet
Lowest carbidopa ratio; 3-4x daily
25 mg/100 mg — immediate-release tablet
Most commonly prescribed starting dose; 3-4x daily
25 mg/250 mg — immediate-release tablet
Higher levodopa dose for patients needing more; 3-4x daily
25 mg/100 mg — extended-release tablet
ER formulation; in shortage as of 2026
50 mg/200 mg — extended-release tablet
ER formulation; partially available; in shortage
23.75 mg/95 mg – 61.25 mg/245 mg — extended-release capsule (Rytary)
Multi-bead ER capsule; 3-5x daily; not in shortage
Various — extended-release capsule (Crexont)
Newest ER capsule approved 2024; twice-daily dosing available; not in shortage
Availability varies significantly by formulation. Generic immediate-release tablets are generally available from multiple manufacturers (Teva, Amneal, Sun Pharma, and others) with spot shortages at individual pharmacies. Extended-release tablets are a different story—they remain on the ASHP drug shortage list as of early 2026, with the 25/100 mg ER strength discontinued by Accord Healthcare.
The shortage stems from manufacturer consolidation after Merck discontinued brand-name Sinemet CR in 2019–2020, leaving the entire ER market to a small number of generic manufacturers with little supply redundancy. Orally disintegrating tablets have been completely discontinued. Brand ER capsule alternatives (Rytary, Crexont) are available but more expensive and require prior authorization.
Finding Sinemet requires checking multiple pharmacies—availability changes week to week. medfinder calls pharmacies near you to check which ones have your exact dose and formulation in stock, saving you hours of phone calls.
Sinemet (carbidopa/levodopa) is not a controlled substance, so it can be prescribed by any licensed prescriber with a valid DEA number—there are no scheduling-related prescribing restrictions. The appropriate type of provider depends on the complexity of the patient's Parkinson's disease management.
Neurologists (movement disorder specialists): Optimal for initial diagnosis, complex dosing management, and managing motor fluctuations
Primary care physicians / internists: Appropriate for stable, established patients on maintenance therapy
Geriatricians: Specialists in older adult care who frequently manage Parkinson's disease
Nurse practitioners (NPs) and physician assistants (PAs): Can prescribe independently in most states
Telehealth is a viable option for established Parkinson's patients needing prescription refills, particularly those in rural areas or with mobility limitations. Initial diagnosis still requires an in-person neurological evaluation. Platforms like Teladoc, MDLive, and insurance-based telehealth services can connect patients with neurologists via video.
No. Sinemet (carbidopa/levodopa) is not a controlled substance and is not scheduled by the DEA. Any licensed prescriber in the United States—including primary care physicians, nurse practitioners, and physician assistants—can write a prescription for it without special DEA registration.
There are no federal restrictions on the number of refills, no requirement for in-person visits to obtain refills (beyond standard care practices), and no limits on prescription length tied to controlled substance law. The medication can be prescribed via telehealth for established patients. The so-called 'eight tablet limit' some patients encounter is based on original FDA labeling language, not controlled substance regulation—it is not a legal dispensing limit.
Nausea and vomiting (especially early in treatment)
Dyskinesia (involuntary movements) with long-term use
Orthostatic hypotension (dizziness when standing)
Drowsiness and sudden sleep episodes
Wearing-off effect between doses
Dark-colored urine or sweat (harmless)
Hallucinations and psychosis
Impulse control disorders (gambling, hypersexuality, compulsive eating)
Vitamin B6 deficiency and seizures (2026 FDA warning — monitor B6 levels)
Neuroleptic malignant-like syndrome (if stopped abruptly — never discontinue suddenly)
Depression and suicidal ideation
Increased melanoma risk (periodic skin examinations recommended)
Know what you need? Skip the search.
Pramipexole (Mirapex)
Dopamine agonist; used in early PD to delay levodopa therapy or as adjunct; lower dyskinesia risk initially; risk of somnolence and impulse control disorders
Ropinirole (Requip)
Dopamine agonist similar to pramipexole; available in standard and extended-release forms; once-daily with Requip XL
Rasagiline (Azilect)
MAO-B inhibitor; once-daily; used in early PD or as adjunct to reduce off-time; generally well tolerated
Rytary (carbidopa/levodopa ER capsules)
Same active ingredients as Sinemet but extended-release multi-bead technology; not in shortage but expensive and requires prior auth
Crexont (carbidopa/levodopa ER capsules)
Newest formulation approved 2024; twice-daily dosing option; not in shortage; alternative when ER tablets unavailable
Prefer Sinemet? We can find it.
Non-selective MAO inhibitors (phenelzine, tranylcypromine)
majorAbsolutely contraindicated — risk of acute hypertensive crisis. Must discontinue MAO inhibitors at least 14 days before starting Sinemet.
Dopamine D2 antagonists (haloperidol, risperidone, metoclopramide)
majorBlock dopamine receptors and reduce Sinemet's therapeutic effectiveness. Avoid if possible; quetiapine is preferred if antipsychotic is needed.
Iron salts and multivitamins with iron
moderateForms chelates with carbidopa and levodopa, significantly reducing absorption. Space iron at least 2 hours from Sinemet dose.
Antihypertensive medications
moderateAdditive hypotensive effect may occur. Monitor blood pressure when starting Sinemet and adjust antihypertensive dosing as needed.
Selegiline (MAO-B inhibitor)
moderateConcurrent use associated with severe orthostatic hypotension. Use with caution and monitor blood pressure closely.
Tricyclic antidepressants
moderateRare reports of hypertension and dyskinesia when combined with carbidopa/levodopa. Monitor closely; SSRIs generally preferred.
High-protein diet
minorDietary amino acids compete with levodopa for gut absorption and blood-brain barrier transport, reducing effectiveness. Take 30-60 minutes before meals.
Sinemet (carbidopa/levodopa) remains the most effective treatment for Parkinson's disease more than 50 years after its introduction. Despite ongoing supply challenges with the extended-release formulation, generic IR tablets are affordable and widely available—making access primarily a matter of finding the right pharmacy, not affordability.
Key 2026 updates include the new FDA warning about vitamin B6 deficiency and seizure risk with long-term use, the approval of Crexont as a new ER capsule alternative, and the continuing ASHP shortage listing for ER tablets. Patients should work closely with their neurologists to ensure their treatment regimen accounts for these developments.
If you are struggling to find Sinemet at a pharmacy near you, medfinder calls pharmacies in your area to identify which ones have your exact dose and formulation in stock, so you can focus on your health rather than endless phone calls.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini